CD30: An important new target in hematologic malignancies

Yehuda E. Deutsch, Tamar Tadmor, Eckhard R. Podack, Joseph D Rosenblatt

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

CD30 is abundantly and selectively expressed on the surface of Hodgkin ReedSternberg cells, anaplastic large cell lymphomas (ALCLs), and other lymphoid malignancies as well as on several non-lymphoid malignancies including selected germ cell tumors. Expression of CD30 on normal cells is highly restricted, thereby allowing differential targeting of malignant cells. CD30, a member of the tumor necrosis factor (TNF)-receptor family has pleiotropic biologic functions, and antibodies targeting CD30 and other TNF family receptors can exhibit both agonistic and antagonistic signaling functions. Recently, antibodydrug conjugates targeting CD30, such as brentuximab vedotin, have shown striking activity in phase I and II trials, with manageable toxicity. This has defined an important emerging role for targeting of CD30 in the setting of Hodgkin lymphoma, ALCL, and possibly other CD30+ malignancies.

Original languageEnglish
Pages (from-to)1641-1654
Number of pages14
JournalLeukemia and Lymphoma
Volume52
Issue number9
DOIs
StatePublished - Sep 1 2011

Fingerprint

Hematologic Neoplasms
Anaplastic Large-Cell Lymphoma
Tumor Necrosis Factor Receptors
Hodgkin Disease
Neoplasms
Germ Cell and Embryonal Neoplasms
Antibodies

Keywords

  • antibody-based immunotherapy
  • brentuximab vedotin
  • CD30
  • Lymphoma and Hodgkin disease

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

CD30 : An important new target in hematologic malignancies. / Deutsch, Yehuda E.; Tadmor, Tamar; Podack, Eckhard R.; Rosenblatt, Joseph D.

In: Leukemia and Lymphoma, Vol. 52, No. 9, 01.09.2011, p. 1641-1654.

Research output: Contribution to journalArticle

Deutsch, Yehuda E. ; Tadmor, Tamar ; Podack, Eckhard R. ; Rosenblatt, Joseph D. / CD30 : An important new target in hematologic malignancies. In: Leukemia and Lymphoma. 2011 ; Vol. 52, No. 9. pp. 1641-1654.
@article{55b02eb19cab450eb1e3454ca69e75de,
title = "CD30: An important new target in hematologic malignancies",
abstract = "CD30 is abundantly and selectively expressed on the surface of Hodgkin ReedSternberg cells, anaplastic large cell lymphomas (ALCLs), and other lymphoid malignancies as well as on several non-lymphoid malignancies including selected germ cell tumors. Expression of CD30 on normal cells is highly restricted, thereby allowing differential targeting of malignant cells. CD30, a member of the tumor necrosis factor (TNF)-receptor family has pleiotropic biologic functions, and antibodies targeting CD30 and other TNF family receptors can exhibit both agonistic and antagonistic signaling functions. Recently, antibodydrug conjugates targeting CD30, such as brentuximab vedotin, have shown striking activity in phase I and II trials, with manageable toxicity. This has defined an important emerging role for targeting of CD30 in the setting of Hodgkin lymphoma, ALCL, and possibly other CD30+ malignancies.",
keywords = "antibody-based immunotherapy, brentuximab vedotin, CD30, Lymphoma and Hodgkin disease",
author = "Deutsch, {Yehuda E.} and Tamar Tadmor and Podack, {Eckhard R.} and Rosenblatt, {Joseph D}",
year = "2011",
month = "9",
day = "1",
doi = "10.3109/10428194.2011.574761",
language = "English",
volume = "52",
pages = "1641--1654",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - CD30

T2 - An important new target in hematologic malignancies

AU - Deutsch, Yehuda E.

AU - Tadmor, Tamar

AU - Podack, Eckhard R.

AU - Rosenblatt, Joseph D

PY - 2011/9/1

Y1 - 2011/9/1

N2 - CD30 is abundantly and selectively expressed on the surface of Hodgkin ReedSternberg cells, anaplastic large cell lymphomas (ALCLs), and other lymphoid malignancies as well as on several non-lymphoid malignancies including selected germ cell tumors. Expression of CD30 on normal cells is highly restricted, thereby allowing differential targeting of malignant cells. CD30, a member of the tumor necrosis factor (TNF)-receptor family has pleiotropic biologic functions, and antibodies targeting CD30 and other TNF family receptors can exhibit both agonistic and antagonistic signaling functions. Recently, antibodydrug conjugates targeting CD30, such as brentuximab vedotin, have shown striking activity in phase I and II trials, with manageable toxicity. This has defined an important emerging role for targeting of CD30 in the setting of Hodgkin lymphoma, ALCL, and possibly other CD30+ malignancies.

AB - CD30 is abundantly and selectively expressed on the surface of Hodgkin ReedSternberg cells, anaplastic large cell lymphomas (ALCLs), and other lymphoid malignancies as well as on several non-lymphoid malignancies including selected germ cell tumors. Expression of CD30 on normal cells is highly restricted, thereby allowing differential targeting of malignant cells. CD30, a member of the tumor necrosis factor (TNF)-receptor family has pleiotropic biologic functions, and antibodies targeting CD30 and other TNF family receptors can exhibit both agonistic and antagonistic signaling functions. Recently, antibodydrug conjugates targeting CD30, such as brentuximab vedotin, have shown striking activity in phase I and II trials, with manageable toxicity. This has defined an important emerging role for targeting of CD30 in the setting of Hodgkin lymphoma, ALCL, and possibly other CD30+ malignancies.

KW - antibody-based immunotherapy

KW - brentuximab vedotin

KW - CD30

KW - Lymphoma and Hodgkin disease

UR - http://www.scopus.com/inward/record.url?scp=80052076003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052076003&partnerID=8YFLogxK

U2 - 10.3109/10428194.2011.574761

DO - 10.3109/10428194.2011.574761

M3 - Article

C2 - 21619423

AN - SCOPUS:80052076003

VL - 52

SP - 1641

EP - 1654

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 9

ER -